Genefrontier Corporation

The University of Tokyo

Chugai Seiyaku Kabushiki Kaisha

Keio University

F. Hoffmann-la Roche Ag

Chiba University

Mikiko Nakamura

Kanehisa Kojoh

Akira Miyakoshi

Kumiko Tsuihiji

Yuki Hayami

Takuya Ueda

Takashi Kanamori

Shizue Katoh

Tomoe Fuse

Shizue Kato

Toshinori Nakayama

Toshihiko Ohtomo

Yasunori Okada

Satsuki Mochizuki

Ya-Chi Chen

Jun Amano

Chiaki Iwamura

The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

Anti-human CD69 antibody, and use thereof for medical purposes

The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy

The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.

Human antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases

According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.

Composition for synthesizing protein with reduced lipopolysaccharide contamination, method for producing protein using said composition

Provided is an antigen-binding protein prepared merely by a method of in vitro selection using the RNF8-FHA domain, which has no intramolecular disulfide bond and functions in cells as it is. One to four loops extending from the FHA domain are randomized, and a recognition site for a target molecule is artificially created on the FHA domain surface to construct an RNF8-FHA domain library. Using the library, an antigen-binding protein is efficiently selected in vitro.

RNF8-FHA domain-modified protein and method of producing the same

Growing community of inventors

Kashiwa, Japan

Mikiko Nakamura